Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

pembrolizumab 111Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 68Cisplatin 67Biopsy 57Nivolumab 56Radiotherapy 51Cyclophosphamide 50Paclitaxel 48durvalumab 38Radiation 38Gemcitabine 37olaparib 32Rituximab 32Etoposide 32Dexamethasone 32Doxorubicin 30Docetaxel 30atezolizumab 29Lenalidomide 27Ipilimumab 27Taxes 26Pemetrexed 26Bevacizumab 25Vincristine 24Cytarabine 24Prednisone 23Platinum 23Radiotherapy, Intensity-Modulated 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Medrol Veriderm × 90 days × Clear all
NCT00792948 2026-05-29

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
97 enrolled 7 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡